

Are you newly diagnosed with metastatic prostate cancer (mPC)?

Look inside to learn about the different types of mPC and a treatment option that is not chemotherapy.



Now FDA approved as early as metastatic prostate cancer diagnosis

Patient portrayal.

 **PLUVICTO[®]**
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

FDA, US Food and Drug Administration.

What is PLUVICTO[®] (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a prescription treatment used to treat adults with metastatic prostate-specific membrane antigen-positive (PSMA+) prostate cancer and are:

- androgen pathway modulation-naïve or -sensitive (mAPMN/S) in combination with hormone therapy, or
- androgen pathway modulation-resistant (mAPMR) after hormone therapy, and
 - appropriate to delay chemotherapy, or
 - have received prior chemotherapy

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?


Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

Please see additional Important Safety Information throughout.

If diagnosed with mPC, understanding your disease is vital

An mPC diagnosis can be overwhelming, but educating yourself and taking an active role in your treatment plan can help you navigate making decisions.

mPC can be treated with hormone therapies that block the effects of testosterone, a key hormone that fuels cancer growth and spread.



Cancer can start in the prostate (a).

In metastatic prostate cancer, it has spread to other parts of the body, such as:

- The bone (b)
- Local (c) or distant (d) lymph nodes
- Other organs (e)

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information I should know about PLUVICTO? (continued)

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

Please see additional Important Safety Information throughout.



There are different types of metastatic prostate cancer (mPC)



Metastatic Hormone-Sensitive Prostate Cancer (mHSPC):

mPC that responds to hormone therapy.

mHSPC is also known as mAPMN/S prostate cancer.



mHSPC can progress over time



Metastatic Castration-Resistant Prostate Cancer (mCRPC):

mPC that has stopped responding to hormone therapy that lowers testosterone.

mCRPC is also known as mAPMR prostate cancer.



Patient portrayal.

~50% of men with mHSPC stop responding to hormone therapy* and progress to mCRPC within 2 years.

Take an active role in your treatment plan and talk to your doctor about PLUVICTO.

*These men stopped responding to hormone therapies that lower testosterone. Hormone therapies can still be effective in slowing cancer growth and lowering prostate-specific antigen (PSA) levels.
mAPMN/S prostate cancer, metastatic androgen pathway modulation-naïve or -sensitive prostate cancer; mAPMR prostate cancer, metastatic androgen pathway modulation-resistant prostate cancer.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including:

Low level of blood cell counts, which may be severe and life-threatening. Tell your doctor right away if you develop any new or worsening symptoms, including:

- Tiredness or weakness
- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

Please see additional Important Safety Information throughout.

 **PLUVICTO®**
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

PLUVICTO is not chemotherapy. It's different.

PLUVICTO is available for men like you




A targeted therapy

with the goal to deliver radiation directly into PSMA+ cells to destroy them from within. It may also affect some nearby healthy cells



Given every 6 weeks for up to 6 doses*

and can sometimes be combined with other mPC therapies



Tested in 3 large clinical studies

and has already treated over 30,000 men

[Click here](#) to find out more about PLUVICTO and if it may be right for you.

*Dosing may change or stop based on disease progression or unmanageable side effects.

PSMA+, prostate-specific membrane antigen-positive.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

Kidney problems, which can be severe. You should stay well hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.

All radiopharmaceuticals, including PLUVICTO, have the potential to **cause harm to an unborn baby**.

- You should use effective contraception during treatment with PLUVICTO and for 14 weeks after your last dose

PLUVICTO may cause temporary or permanent **infertility**.

Please see additional Important Safety Information throughout.



Find out if PLUVICTO could be right for you—ask your doctor about your PSMA status


PSMA, or prostate-specific membrane antigen, is normally found on prostate cells, and its levels are up to 1000 times higher in prostate cancer cells. If you have higher levels of PSMA compared to a standard level, your PSMA status is considered PSMA positive (PSMA+).

>80% of men with prostate cancer have PSMA+ status, and you could too.

PSMA is different than PSA



PSA, or prostate-specific antigen, is a protein made by the prostate that is numerically measured through a blood test. High levels of PSA can tell you and your doctor that cancer may be present somewhere in the body.



PSMA, on the other hand, is detected with a PSMA-PET scan. This can show where the cancer has spread in your body and if your PSMA status is considered PSMA positive (PSMA+).

A key next step is a PSMA-PET scan.
Ask your doctor about getting one.

PET, positron emission tomography.

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of PLUVICTO include:

- Decreased blood cell counts
- Laboratory abnormalities
- Tiredness
- Dry mouth
- Nausea
- Kidney problems

Please see additional Important Safety Information throughout.



PLUVICTO

may be the right next
step for you



Ask your doctor
about your
PSMA status



Patient portrayal.

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of PLUVICTO include (continued):

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout.
Please see full [Prescribing Information](#).

 **NOVARTIS**

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2026 Novartis

 **PLUVICTO[®]**
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

7/26

FA-11646327